Pancreatic cancer is a leading cause of cancer-related deaths worldwide and presents a 5-year survival rate of under 12%. Most patients are diagnosed at an advanced stage, with over half of them presenting with metastatic disease at diagnosis.
Antibodies targeting CD269 and GPRC5D have shown unprecedented clinical efficacy in the treatment of multiple myeloma (MM), but many patients still develop progressive disease. It was hypothesized that dual-targeting T-cell immunotherapies might improve the efficacy by addressing the difficulty of heterogenous target expression and preventing resistance development due to antigen escape.
Disco Pharmaceuticals GmbH announced the final close of its seed round at €36 million (US$42 million), as it shapes up novel targets it has discovered with its surfaceome platform technology for formal preclinical development.
Ascentage Pharma (Suzhou) Co. Ltd. and China Pharmaceutical University have identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker reported to be useful for the treatment of cancer.
Scientists at East China Normal University and East China University of Science & Technology have synthesized 5’-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.
Chengdu Kangnuoxing Biopharma Inc. and Keymed Biosciences Co. Ltd. have disclosed antibody-drug conjugates (ADCs) comprising antibody or antigen binding fragments targeting cadherin-17 (CDH17) linked to a cytotoxic drug through a linker.
Peptidream Inc. has announced approval of a clinical research protocol for [64Cu]PD-29875, a Claudin 18.2-targeting 64Cu-labeled radiopharmaceutical, in patients with gastric cancer.
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
Astrazeneca plc has provided data for their CD22-targeting antibody-drug conjugate (ADC) AZD-4512 under development for the treatment of B-cell malignancies, which still have significant rates of disease resistance and relapse, as well as treatment-related toxicities.
Shanghai Best-Link Bioscience LLC has described polymer-drug conjugates comprising a polymer covalently linked to a cytotoxic drug through a linker and its nanoparticles reported to be useful for the treatment of cancer.
RSS
